Moderna's full pipeline may fuel long-term growth.
Moderna Inc.’s shares plunged after U.S. regulators refused to review its novel mRNA flu vaccine, dealing a major blow to the company as it seeks more products beyond its COVID shot. The U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results